亚盛药业APG-3288片启动I期临床 适应症为血液系统恶性肿瘤

新浪财经
Feb 11

药物临床试验登记与信息公示平台数据显示,苏州亚盛药业有限公司的一项在复发/难治性血液系统恶性肿瘤患者中评估APG-3288的安全性、药代动力学和初步疗效的I期研究已启动。临床试验登记号为CTR20260416,首次公示信息日期为2026年02月11日。该药物剂型为片剂,用法用量为每日一次(QD)口服给药,28天为一个周期,用药时程持续直至疾病进展、出现不可耐受的毒性或符合其他治疗终止标准(以先发生...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10